Company intelligence / Profile preview

ViVerita Therapeutics

Boston, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

ViVerita Therapeutics has not yet reported clinical trial results but has established a robust preclinical pipeline based on advanced in vivo genetic screening and faithful disease models targeting novel cancer drivers. As of Oct 2025, there are no disclosed clinical-stage molecules or public leads.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologicCRISPR-based therapy
Industry: Biotech

Partnerships

Boehringer Ingelheim

Beyond the preview

Go deeper on ViVerita Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViVerita Therapeutics.

Explore the full profile